Matinas BioPharma to Present at the MicroCap Conference
Matinas BioPharma to Present at the MicroCap Conference
- Presentation with live audio webcast on Monday, October 1st at 8:30 AM ET -
BEDMINSTER, N.J., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on enabling targeted intracellular delivery of life-changing medicines using its proprietary lipid nano-crystal (LNC) platform technology, announced today that Jerome D. Jabbour, Chief Executive Officer, will present at the MicroCap Conference on Monday, October 1, 2018 at 8:30 AM ET in New York, NY.
As part of his presentation, Mr. Jabbour will provide a corporate update and will discuss the Company’s differentiated LNC drug delivery platform which offers an intracellular drug delivery solution with potential advantages for a range of therapeutics, including small molecules, nucleic acid polymers, proteins, peptides, vaccines, as well as the targeted delivery of gene editing technologies. He will review the Company's lead platform-validating product candidate, MAT2203, and its streamlined and risk-mitigated development program focused on a potential pivotal Phase 2 trial of MAT2203 for the prevention of invasive fungal infections (IFIs) in patients with acute lymphoblastic leukemia, an area of significant unmet medical need. Mr. Jabbour will also address the Company’s second LNC product candidate, MAT2501, which, as potentially the first orally available aminoglycoside, is being positioned as a differentiated therapy for the treatment of non-tuberculous mycobacterium (NTM) infections, as well as other acute bacterial infections.
Additionally, Mr. Jabbour will discuss MAT9001, the Company’s proprietary prescription-only omega-3 fatty acid-based composition under development for hypertriglyceridemia (TG>500 mg/dL), which has demonstrated statistically significant superiority versus Vascepa® (icosapent ethyl) in reducing serum triglycerides, total- and non-HDL-cholesterol, apolipoproteins and PCSK9 levels. MAT9001 is a next-generation omega-3 fatty acid composition, comprising docosapentaenoic acid (DPA), a potent but less prevalent omega-3 fatty acid with very unique properties, and other omega-3 fatty acids. MAT9001 was developed based on the newest scientific advancements in the field, incorporating and building upon the knowledge of almost 40 years of scientific research in the omega-3 discipline. Given recently announced developments in the cardiovascular space and the potential best-in-class data generated by MAT9001 to date, Matinas is well prepared to be opportunistic in evaluating strategic alternatives to further develop and commercialize MAT9001 on a global and/or regional basis.
In addition to the presentation, management will also be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference.
A live audio webcast of the presentation will be available on the Events page of the Investors section of the Company’s website (www.matinasbiopharma.com). A webcast replay will be accessible for 90 days following the live presentation.
About Matinas BioPharma
Matinas BioPharma is a clinical-stage biopharmaceutical company focused on developing innovative medicines using its lipid nano-crystal (LNC) platform delivery technology. The Company's proprietary, disruptive technology utilizes lipid-crystal nano-particle cochleates to nano-encapsulate small molecules, oligonucleotides, vaccines and other medicines potentially making them safer, more tolerable, less toxic and orally bioavailable.
The Company's lead anti-fungal product candidate, MAT2203, positions Matinas BioPharma to become a leader in the safe and effective delivery of anti-infective therapies utilizing its proprietary LNC formulation technology.
Forward Looking Statements: This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company's anticipated capital and liquidity needs, strategic focus and the future development of its product candidates, including MAT2203, the anticipated timing of regulatory submissions, the anticipated timing of clinical studies, the anticipated timing of regulatory interactions, the Company’s ability to identify and pursue development and partnership opportunities for its products or platform delivery technology on favorable terms, if at all, and the ability to obtain required regulatory approval and other statements that are predictive in nature, that depend upon or refer to future events or conditions. All statements other than statements of historical fact are statements that could be forward-looking statements. Forward-looking statements include words such as "expects," "anticipates," "intends," "plans," "could," "believes," "estimates" and similar expressions. These statements involve known and unknown risks, uncertainties and other factors which may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to obtain additional capital to meet our liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials of our product candidates; our ability to successfully complete research and further development and commercialization of our product candidates; the uncertainties inherent in clinical testing; the timing, cost and uncertainty of obtaining regulatory approvals; our ability to maintain and derive benefit from the Qualified Infectious Disease Product (QIDP), Orphan and/or Fast Track designations for MAT2203, which does not change the standards for regulatory approval or guarantee regulatory approval on an expedited basis, or at all; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; and the other factors listed under "Risk Factors" in our filings with the SEC, including Forms 10-K, 10-Q and 8-K. Investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this release. Except as may be required by law, the Company does not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Matinas BioPharma's product candidates are all in a development stage and are not available for sale or use.
Jenene Thomas Communications, LLC
Phone: +1 (833) 475-8247
Scient Public Relations
Phone: + 1 (917) 763-8106
Source: Matinas BioPharma Holdings, Inc.